List view / Grid view

Issue #1 2017

 

article

Assays In-Depth Focus 2017

15 March 2017 | By , , ,

HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…

article

Biomarkers In-Depth Focus 2017

15 March 2017 | By , , , , ,

Drug developers sometimes think of imaging as an emerging discipline. But John Waterton, Paul Hockings, Juliana Maynard and Caleb Roberts explain how imaging biomarkers are transforming drug development. Francesco Gatto and Jens Nielsen, from the Chalmers University of Technology in Sweden, discuss moving towards systems biomarkers for cancer diagnosis...

article

Antibodies In-Depth Focus 2017

15 March 2017 | By

Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...

article

Nanoparticle-mediated enzyme delivery for application in cancer therapy

9 March 2017 | By , , ,

Enzyme therapy is a promising form of cancer treatment. The specific nature of enzyme and substrate interaction gives enzyme therapy an edge compared to standard non-specific therapies such as radiation and chemotherapy. However, since most of these enzymes are of a foreign nature, the delivery of these immunogenic enzymes has…

article

How imaging biomarkers are transforming drug development

15 January 2017 | By , , ,

Drug developers sometimes think of imaging as an emerging discipline, full of esoteric technologies of marginal relevance to real-world clinical drug development. In fact, the opposite is true: imaging measurements (imaging biomarkers) are used daily in drug development and in personalised medicine. They assess target engagement and receptor occupancy in…